Predicting Treatment Effects of a New‐to‐Market Drug in Clinical Practice Based on Phase III Randomized Trial Results
- 14 July 2023
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (4) , 853-861
Abstract
Trial results may not be generalizable to target populations treated in clinical practice with different distributions of baseline characteristics that modify the treatment effect. We used outcome models developed with trial data to predict treatment effects in Medicare populations. We used data from the Randomized Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY), which investigated the effect of dabigatran vs. warfarin on stroke or systemic embolism (stroke/SE) among patients with atrial fibrillation. We developed outcome models by fitting proportional hazards models in trial data. Target populations were trial-eligible Medicare beneficiaries who initiated dabigatran or warfarin in 2010-2011 ("early") and 2010-2017 ("extended"). We predicted 2-year risk ratios (RRs) and risk differences (RDs) for stroke/SE, major bleeding, and all-cause death in the Medicare populations using the observed baseline characteristics. The trial and early target populations had similar mean (SD) CHADS(2) scores (2.15 (SD 1.13) vs. 2.15 (SD 0.91)) but different mean ages (71 vs. 79 years). Compared with RE-LY, the early Medicare population had similar predicted benefit of dabigatran vs. warfarin for stroke/SE (trial RR = 0.63, 95% confidence interval (CI) = 0.50 to 0.76 and RD = -1.37%, -1.96% to -0.77%, Medicare RR = 0.73, 0.65 to 0.82 and RD = -0.92%, -1.26% to -0.59%) and risks for major bleeding and all-cause death. The time-extended target population showed similar results. Outcome model-based prediction facilitates estimating the average treatment effects of a drug in different target populations when treatment and outcome data are unreliable or unavailable. The predicted effects may inform payers' coverage decisions for patients, especially shortly after a drug's launch when observational data are scarce.Keywords
This publication has 39 references indexed in Scilit:
- A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative dataPharmacoepidemiology and Drug Safety, 2012
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- An automated database case definition for serious bleeding related to oral anticoagulant usePharmacoepidemiology and Drug Safety, 2011
- Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-One Matching on the Propensity ScoreAmerican Journal of Epidemiology, 2010
- Assessing the Performance of Prediction ModelsEpidemiology, 2010
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Validation of ICD‐9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health dataPharmacoepidemiology and Drug Safety, 2007
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationCirculation, 2006
- Failure of ICD‐9‐CM Codes to Identify Patients with Comorbid Chronic Kidney Disease in DiabetesHealth Services Research, 2005
- Better Bootstrap Confidence IntervalsJournal of the American Statistical Association, 1987